Thank you very much, Mr. Chair.
Ms. Tassi, we are talking about new treatments, but I want to come back to the contracts that were signed with Moderna, Pfizer and AstraZeneca.
Is it possible, on the one hand, to know the value of these contracts and, on the other hand, to see these contracts?